In this Section |
239816 Care pattern and survival of colorectal cancer patients in TaiwanMonday, October 31, 2011
Background: Colorectal cancer is the 3rd leading cancer death in Taiwan. The best treatment modalities of stage II and III colorectal cancer patient are still controversial.
Objective: To analyze the survivals of stage II and III colorectal cancer patients received different patterns of treatment. Methods: This retrospective cohort study included stage II and III incident colorectal cancer patients from 2004 to 2006 identified in Taiwan Cancer Database (TCDB). Subjects were stratified by staging. Survivals of the patients receiving different treatment strategies were analyzed. Cox regression was used to compare the survival duration of patients with different care patterns by controlling demographic, disease status and provider's characteristics. Results: There were 3,981, 4085 subjects included in this study with the staging of Carcinoma in stage II and III respectively. The most frequent treatment strategies adopted in stage II patients were surgery only (OP), in contrast to surgery combine chemotherapy (OPCT), surgery combine chemotherapy and radiotherapy (OPCTRT). While in stage III patients, the most frequent care pattern was OPCT. After adjustment the confounding factors, we found that OPCT group tended to have lower risk of mortality compare to OP in stage II patients, however, OPCTRT group was not. For those stage III patients, both “OPCT” and “OPCTRT”, compared to OP group, had offered longer survival to the patients. . Conclusions: This analysis suggests that, for stage II and III colorectal cancer, combined surgery and chemotherapy offers longer patient survival than treatments with surgery alone.
Learning Areas:
Clinical medicine applied in public healthPublic health or related organizational policy, standards, or other guidelines Public health or related research Learning Objectives: Keywords: Therapies, Taiwan Health
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I am qualified to present because I am a co-PI of the cancer care evaluation program, participate in design, analyze this study. I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: Current Issues in International Cancer Prevention and Control
See more of: Cancer Forum |